Mount Sinai Medical Center shared on LinkedIn:
“For years, treating women with advanced or recurrent endometrial cancer has started with chemotherapy.
A global Phase 3 trial led by one of our own asked whether, for some women, it could be removed entirely.
Dr. Brian Slomovitz, Director of Gynecologic Oncology and Deputy Director of the Braman Comprehensive Cancer Center, served as global principal investigator of KEYNOTE-C93.
The results were presented today in the ESMO 2026 Presidential Symposium in Madrid and published simultaneously in The Lancet.
In women with mismatch repair deficient (dMMR) tumors, immunotherapy alone reduced the risk of disease progression or death by 43% compared with chemotherapy, and patients reported improved quality of life. Overall survival data are still maturing.
KEYNOTE-C93 was one of 12 studies selected for ESMO’s Presidential Symposia, and women treated at Braman Comprehensive Cancer Center were among its participants.”
You can also read: KEYNOTE-C93 Trial: Pembrolizumab Versus Chemotherapy in dMMR Endometrial Cancer
